The global market for Gestational Trophoblastic Disease (GTD) treatment is experiencing steady growth, driven by increased awXareness, advancements in diagnostics, and therapeutic innovations. The disease, which includes conditions such as molar pregnancies and choriocarcinoma, is primarily treated with surgery, chemotherapy, and in some cases, radiation therapy. Significant strides in molecular diagnostics and the development of targeted therapies have improved treatment outcomes. Recent years have seen an increase in abnormal pregnancies, which, in turn, has raised the incidence of GTD. This has spurred advancements in both medical research and treatment options. For instance, new targeted therapies and immunotherapies are gaining attention for their ability to offer more personalized treatments with fewer side effects. Additionally, telemedicine and remote healthcare are making treatment more accessible, especially in developing regions.
